Wigen Biomedicine Technology (Shanghai)

Wigen Biomedicine is a clinical-stage biotechnology company based in Shanghai, China, specializing in the discovery and development of innovative small molecule precision medicines for oncology. The company leverages a structure-based drug design platform to target well-validated but difficult-to-drug oncogenic drivers, with a particular focus on the RAS/MAPK and cell cycle pathways. Its lead programs include highly selective inhibitors targeting KRAS mutations, such as G12C and G12D, as well as next-generation kinase inhibitors. Wigen aims to address significant unmet medical needs in cancer treatment through both internal R&D and strategic collaborations.